A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export/SINE™ Compound KPT-330 in Patients With Advanced Hematological Malignancies
The purpose of this research study are to find out more information such as: the highest
dose of KPT-330 that can be given safely, the side effects it may cause, to examine how the
body affects the study drug concentrations in the blood (pharmacokinetics or PK), to examine
the effects of this study drug on the body (pharmacodynamics or PDn) and to gain some
information on its effectiveness in treating cancer.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society